AAV9–shRNA–SOD1 based gene therapy(University of California San Diego/Neurgain Technologies)

N/A

Report date: 2025/01/26 18:11:32
NME

Base Information

Drug NameAAV9–shRNA–SOD1 based gene therapy(University of California San Diego/Neurgain Technologies)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNA
Mechanisms of ActionSuperoxide dismutase inhibitors
TargetsSuperoxide dismutase
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San Diego
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A